Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022582 | 0.90 | JAK1 (0.58) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30023088 | 0.87 | JAK1 (0.58) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30022445 | 0.80 | JAK1 (0.51) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30021697 | 0.80 | JAK1 (0.55) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3999994 | 0.79 | SLC6A2 (0.57) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30022181 | 0.77 | JAK1 (0.49) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24855522 | 0.73 | ALDH1A1 (0.56) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29790471 | 0.73 | ALDH1A1 (0.56) | JAK1TYK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8347455 | 0.69 | CCNC (0.56) | LMNATP53MAPTPROKR1HPGD | |
| SCHEMBL1823350 | 0.68 | SLC6A2 (0.56) | JAK1TYK2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | JAK1 2/4885TYK2 8/4885SLC6A2 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.